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vABSTRACT
Age-related macular degeneration (AMD) is the leading cause of central vision loss
in the developed world. In the case of wet AMD, it can be managed through serial
intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents.
However, sometimes the treatment is ineffective. Given that half-life time of the
drug is limited, one possible cause of the ineffective treatment is inefficient drug
mixing in the eye. Here, we focus on the understanding of drug mixing in vitreous
chamber and parameters that could potentially influence mixing profiles. Both
movement-driven method and thermal-driven method are explored. The in-vitro
study outcomes will not only be useful for achieving fundamental understandings
of fluid dynamics in the eye, but also helpful in developing a better strategy for
intravitreal injection and improving the quality of care for patients.
vi
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1C h a p t e r 1
INTRODUCTION
1.1 Background
Anatomy of the eye
Human eye is a very delicate structure, with 80% of its space between the lens
and retina filled with a fluid-like gel, vitreous humor. Vitreous humor is composed
of approximately 98–99% water with trace amounts of hyaluronic acid, glucose,
anions, cations, ions, and collagen (K. S. Scott and Oliver, 1999). It is a very
important space for eye disease treatments as well because a lot of the treatment
processes occur in this space. In the center of the retina, there is a small but
important area called the macula. It is a very critical structure as it allows us to
see details of objects in front of us. (American Academy of Ophthalmology) The
macula encounters diverse issues as people get older. When it happens, patients
usually experience severe vision loss if they don’t receive proper treatment. To name
a few macula-related diseases: branch retinal vein occlusion, macular degeneration
(dry or wet), retinal detachment, retinitis pigmentosa, etc. In this study, we focus
on investigating how drugs travel/mix in the vitreous chamber to reach the macula
and treat macula-related eye diseases. A detailed demonstration of the anatomy of
the eye can be found in Figure 1.1 below.
Eye Disease Background and Treatment Challenges
As mentioned earlier, many eye diseases are macula-related. In this study, we
would like to start with improving the treatment efficacy for age-related macular
degeneration (AMD), since it is the leading cause of central vision loss in the
developed world. The primary treatment for AMD, intravitreal injection, is a very
representative treatment method for many other eye diseases as well. Therefore, the
study outcome can make a broader impact.
Patients with AMD see a dark spot in the center of their vision. There are two forms
of the disease. The “dry” form of the disease is characterized by yellow deposits or
2Figure 1.1: Anatomy of the eye (figure adapted from verywellhealth.com) The solid
arrow indicates the space filled with vitreous humor; the dashed arrow indicates the
typical location of macula.
choroidal neovascularization that develops underneath the retinal pigment epithe-
lium. Fluid and blood leak through these abnormal vessels, creating scar tissues.
In the “wet” form, normal macular tissues are lost which also cause severe vision
loss. A typical vision of a patient with AMD disease is shown in Figure reffig:amd
below.
In the case of wet AMD, it can be managed through serial intravitreal injections
of anti-vascular endothelial growth factor (anti-VEGF) agents. During such an
injection, an ophthalmologist injects 50 microliters of the drug into the vitreous
chamber of a patient every four weeks. These anti-VEGF injections are effective
at stabilizing, often improving visual acuity in patients with wet AMD. A similar
treatment method can also be used to treat diseases such as diabetic macular edema,
retinal vein occlusion, and other vascular disorders.
The injection interval usually takes about four weeks. Ophthalmologists observe
changes in patients’ visual acuity to determine if another injection is needed. For
each injection, the ophthalmologist uses a 27 Gauge or 30 Gauge needle to inject
50 microliters of drug solution into the vitreous chamber. Although effective,
intravitreal injection is not a perfect solution for every patient, and it potentially
causes many complications such as intraocular inflammation, retinal detachment,
traumatic lens damage, and sustained ocular hypertension. To reduce the frequency
3of injections but still maintain the treatment efficacy, a possible strategy is to increase
drug delivery efficiency during each injection. The focus of this study is to explore
various ways to increase drug delivery efficiency.
Figure 1.2: A typical image that a patient with AMD disease sees (figure adapted
from Bausch.com) As it is shown in the image, the patient would experience blurred
vision, and a dark spot in the center of the vision, as well as distortion of straight
lines.
Figure 1.3: Intravitreal injection procedure (Source: Karl Brasse, MD, Eyeland
Design) Drugs injected into the vitreous chamber exit near the front of the eye.
4During an injection process, the needle tip is positioned at 3 to 4 mm posterior to
limbus. Therefore, the drug usually exits the syringe tip at a position that is closer to
the front of the eye. Figure 1.3 demonstrates a typical intravitreal injection process.
Once the drug enters the vitreous chamber, there are two elimination routes, as
indicated in Figure 1.4: anterior and posterior. For anterior elimination, the drug
must diffuse in the vitreous to gain further access to the aqueous humor. This would
then allow the drug to enter the blood stream. The posterior route requires that
the drug must diffuse in the vitreous and then cross the endothelia and epithelia of
blood-ocular barriers. These barriers are quite selective in determining the type of
molecules that can pass. The exact sites of action for VEGF binding activity of
the drug are still not known. However, it is anticipated that both diffusion routes
(anterior and posterior) can be involved in the drug transport activities. The diffusion
speed depends largely on the individual’s physiological condition as well as drug
molecule weight. As a result, drugs usually have very different delivery speeds
in the vitreous humor: small molecule drugs can diffuse much faster, whereas the
mobility is restricted for large molecule drugs.
Figure 1.4: wo drug elimination routes for drug in vitreous chamber: anterior (left)
vs posterior (right) Maurice and Mishima, 1984 Anterior route (labeled in blue)
is for drugs to diffuse in the vitreous to enter aqueous humor and then reach the
blood stream; posterior route (numbered in 2, 3, and 4) is for drugs to diffuse in the
vitreous and then cross the blood-retinal and blood-aqueous barriers.
To deepen our understanding of the challenge in drugmixing process via diffusion, it
is helpful to understand the meaning of anti-VEGF agents first. There are a few dif-
ferent anti-VEGF agents that are used for treating eye diseases. Taking bevacizumab
5as an example, bevacizumab is a recombinant humanizedmonoclonal IgG1 antibody
that contains human framework regions and murine complementarity-determining
regions. Bevacizumab has an approximate molecular weight of 149 kDa (RxList,
Avastin). Avastin is the brand name for bevacizumab. Avastin (bevacizumab) is
a colorless to pale brown solution and is usually supplied in 100 mg and 400 mg
preservative-free single-dose vials. For a 100 mg product, it is formulated in 240
mg α,α-trehalose dihydrate, 23.2 mg sodium phosphate (monobasic, monohydrate),
4.8 mg sodium phosphate (dibasic, anhydrous), 1.6 mg polysorbate 20, and Water
for Injection, USP. Therefore, water is the main carrier of the drug in the delivery
process. Since the majority of the AMD patients are among the older population,
their vitreous are usually more fluid-like than gel-like. More details regarding the
change in vitreous properties with aging process will be explained in the following
sections. Overall, the time it takes for drugs to deliver to target tissue via pure
diffusion can be approximately estimated by calculating the time it takes for water
to diffuse in water. Table 1.1 below shows a list of empirical diffusion constants.
((Yorston, 2014a),(Miller, 1924))
molecule measuredcontext
diffusion
coefficient
(µm2/s)
BNID
water water 2000 104087, 106703
oxygen water 2000 104440
tRNA (≈ 20kDa) water 100 107933,107935
protein (≈ 30kDa GFP) water 100 100301
protein (≈ 30kDa GFP)
eukaryotic
cell (CHO)
cytoplasm
30 101997
protein (≈ 30kDa GFP) rat liver mi-tochondria 30 100300
Table 1.1: is adapted from source: (Milo and Phillips, 2015). The diffusion
coefficient of water molecule in water is approximately 2000 µm2/s; the diffusion
coefficient for protein of 30kDa in water is approximately 100 µm2/s.
To estimate the time scale τ for a particle to travel distance x, we can use τ ≈
x2/D. Since the average size of a human eye is 24.5 mm in diameter, τ ≈
(24.5mm)2/(2000µm2/s) = 83 hrs, which is approximately 4 days. This theoretical
calculation is consistent with our experimental observations. In our experiment,
we injected water-dissolved dye into water and observed how long it took for the
6dye/water mixture (1 : 50 ratio) to travel 10 mm vertical distance. It took about 20
hrs in total, which was as expected.
Based on this calculation result, it raises a concern that drug delivery by pure
diffusion might be taking too long, given that the vitreous half-life of anti-VEGF is
quite limited and can range from a few hours to a few days. ((Stewart, 2018),(Kim,
Robinson, and Csaky, 2009)) In addition, the diffusion coefficient of protein of
molecular weight 30kDa is 100µm2/s in water, which is much slower than water
diffusion in water. Anti-VEGF agents are usually large molecules (> 150kDa).
The diffusion rate can be much slower since the mobility of large molecules is
usually restricted. This is also confirmed by various research studies summarized
in (Del Amo Eva et al., 2017). Figure 1.5 below summarizes diffusion coefficients
of molecules and particles in vitreous, liquefied vitreous, and water.
Figure 1.5: Diffusion coefficients of molecules and particles in the vitreous. (Source
(Del Amo Eva et al., 2017))
Therefore, to effectively increase injection efficiency, drugs cannot solely rely on
diffusion via anterior or posterior diffusion routes, and convection needs to be
introduced into the scenario. Additionally, another goal of this study is to promote
fluid mixing in the eye in a minimally invasive manner. To summarize the two
objectives, they are to 1) effectively induce convection in the drug delivery process
in the eye to accelerate drug transport efficiency, 2) and promote flow circulation in
the eye to facilitate better drug mixing for improved treatment efficacy. It is worth
noting that there hasn’t been much study of the role of convection flow in promoting
7drug distribution in the eye in the past. (Del Amo Eva et al., 2017) Our study
outcome can offer great insights to be incorporated into the clinical procedure for
improved patient care.
Previous Treatment Efforts and Previous Research Efforts
Several differentways to increase drug delivery efficacy in the eye have been explored
both clinically and academically. Clinically, there are four delivery alternatives and
they are summarized in Figure 1.6 below. These alternative methods are topical,
systemic, implants, and trans-scleral. These various methods are either designed in
an attempt to bypass the two diffusion routes in the eye, or to alleviate the potential
side effects.
Figure 1.6: Schematic drawings of various drug delivery methods for treatment of
AMD (Holz, Schmitz-Valckenberg, and Fleckenstein, 2014) The target area (mac-
ula) can be reached by administrations via various routes: topical delivery to the
surface of the eye, trans-scleral delivery underneath the conjunctiva, direct injection
(injection or implant), and systematical delivery via oral tablets.
Topical drops must diffuse across a few layers to reach the target tissue, these layers
include tear film, cornea, iris, ciliary body, and vitreous. This can severely dilute the
fraction of drug reaching the target issue. Systemic delivery such as tablets can result
in a poor dose-response profile. (Geroski and Edelhauser, 2000) Ocular implant
takes the same idea as intravitreal injections and thus can also benefit from our study
8outcomes. Trans-scleral administration injects drugs via a region surrounding the
eye and experiences the same issue that exist in topical administration: the overall
retinal bioavailability is very low (in the range of 0.1%) after such an administration,
which is not an ideal choice for retinal drug delivery. (E.M. del Amo et al. 2017)
Overall, intravitreal injection is so far the mostly practiced as well as the most
effective treatment for retinal drug delivery.
In the research field, scholars have also made great efforts in understanding fluid
flow in the eye from both animal study and computational perspectives. In the
animal studies, experiments were performed using bovine or rabbit eyes. However,
these structures are not physiologically identical to human eyes. Moreover, some
of the eye functions might change once vitreous humor is sampled from a deceased
animal. Therefore, these study results are insightful but not straightforward.
1.2 Organization of the thesis
The first part of the thesis focuses on the introduction and discussion of eye disease
background, various treatment methods, and previous studies. In the following
sections, two different methods for driving convective flow in the eye are introduced:
one through lateral movements (motional-driven) and one through heating/cooling
(thermal-driven). The detailed experimental setup, results, and implications will be
discussed in their respective sections.
9C h a p t e r 2
DRUG DELIVERY IN THE EYE UNDER LATERAL
MOVEMENTS
2.1 Introduction
Various eye movements and their corresponding functions
There are four basic types of eye movements: saccades movements, smooth pursuit
movements, vergence movements, and vestibule-ocular movements.
1) Saccades movements are rapid movements and the eyes abruptly change the point
of fixation during such movements. In daily life, saccades movements of the eye
happen in many scenarios, ranging from small movements made during reading and
large movements made when a person is simply looking around. It can also occur
during sleep.
2) Smooth pursuit is much slower compared with saccades movement. It facilitates
voluntarily tracking a moving stimulus.
3) Vergence movement is quite different than the other two in the sense that it is
disconjugate, which means eyes can move in different directions.
4) Vestibule-ocular movements compensate for head movements so the eyes are
stabilized relative to the external world, which can help with stabilizing visual
images on the surface of the retina when the head moves. These four movements
can essentially be broken down into three fundamentalmotions: rapid lateralmotion,
rotating motion, and slow lateral motion.
Eye Model
The human eye has a complicated structure. Instead of trying to reproduce every
single detail in the eye, it is important to grasp the most important features to acquire
critical insights experimentally. The content below explains the main structural
challenges that people see in human eyes as well as selection criteria when the eye
model was built for our study.
1) Liquid concentration is not uniformly distributed in the eye. Vitreous humor is
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composed of 98% to 99% water and 1% other ingredients. This 1% other ingre-
dients, the majority of which are collagen and hyaluronan, has various distribution
in different regions of the eye. (Figure 2.1) For the drug to reach the retina via the
posterior route, it must first travel across the central vitreous chamber and then pass
the vitreous cortex to reach the back of the eye. Further, even by considering the
anterior route, the drug still needs to diffuse through the vitreous to join the aque-
ous flow. Therefore, effectively promoting drug mixing in the eye can potentially
facilitate drug eliminations via both routes.(Gaudana et al., 2010)
Figure 2.1: Variations in concentrations in the vitreous ((Purves et al., 2001)) As
it is demonstrated in the figure, hyaluronic acid and collagen are not uniformly
distributed within the vitreous. The highest concentration is in vitreous cortex,
which is the region that is the closest to retina. The central area (central vitreous) is
more liquid like, followed by basal vitreous.
2) Components of human vitreous change consistently as people age. As shown
in Table 2.1, vitreous is a 100% gel solution when we are born and liquefaction
gradually happens as we get older. This is one factor that explains the discrepancy in
treatment efficacy among various individuals. Many other factors include ethnicity,
genetics, and special procedures performed (for example, vitrectomy).
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Age (years) Gel Volume (cm3) Liquid Volume(cm3)
Birth 1.6 0
5 3.3 0
10 3.5 0.7
30 3.9 0.9
50 3.5 1.3
70 2.8 2
90 2.2 2.6
Table 2.1: Change in gel and liquid volume of the human vitreous with age (Source:
(E. Balazs, 1993),(E. A. Balazs, 1982)) The vitreous is more gel-like in childhood;
the liquid vitreous occupies almost half of the vitreous by 70s.
Based on the two above-mentioned structural challenges, one interesting parameter
to look at is the effect of density/viscosity difference between the injected drug and
the vitreous to understand how drug flow proceeds in various environments. Since
regional distributions of liquid and gel components are unclear and it obviously
differs case by case, we start with a vitreous model of uniform density/viscosity
distribution to get a generalized understanding.
To determine the range of physical properties values of human vitreous, we refer to
the analysis conducted by (K. R. Murthy et al., 2014). It states that the viscosity of
human vitreous is two to four times greater than water, which gives vitreous humor
a gelatinous consistency. This conclusion is derived based on a study conducted
by John Locke, M.D. and Ross Morton, M.D. (Locke and Morton, 1965) The
measurements were performed based on 177 samples obtained post-mortem from
97 donors at the Institute of Pathology, McGill University. In addition, during a
vitrectomy operation, vitreous humor of the patient being treated is replaced by
0.9% saline solution. Furthermore, AMD usually affects populations of age 50 and
older, whose vitreous humor is more liquid-like than gel-like. Based on these facts,
it was decided that both 0.9% saline and glycerol/water mixtures at various ratios
were used to make “vitreous humor” in our study. A summary of these material
properties can be found in Table 2.2 below.
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Material Type Viscosity (mPa · s) Density(kg/m3)
Water at 25 Celsius 0.9 1000.0
Saline (0.9% NaCl) 1 1063.3
Human Vitreous 1-3.6 1005.3–1008.9
Glycerol/Water Mixture (1:5) 1.7 1046.8
Glycerol/Water Mixture (2:5) 2.7 1081.5
Glycerol/Water Mixture (1:10) 1.3 1024.5
Table 2.2: Comparison of Material Properties
13
Variations on Injection Sites
As mentioned earlier, during an intravitreal injection session, an ophthalmologist
uses a 27 gauge or 30 gauge needle to inject 50 microliters of drugs into the
vitreous chamber of a patient’s eye. The injection position is usually 3 to 4 mm
posterior to limbus (Figure 2.2) and target at the central region.((Wilson and A.
Scott, 2013),(Yorston, 2014b)) Given that the average diameter of the eye is around
24-mm, the injection spot is quite close to the front of the eye. Therefore, it might
not be an ideal entry spot for effective drug delivery in the eye. Furthermore, human
eye size varies case by case, so if the same protocol is performed for every individual,
the treatment efficacy could certainly vary. ((Akinkunmi, Jahn, and Giovambattista,
2015),(Cristancho et al., 2011),(Frederick, David, et al., 2015))
Therefore, besides lateral movements, another objective for this motion-drive study
was to explore the effects of varying injection sites on drug mixing profiles. These
three injection sites were studied: side injection (which is similar to the actual
intravitreal injection process), center injection (which is more towards the center
and more in depth), and bottom injection (which is the deepest among the three).
More details can be found in the experimental design methods section.
Figure 2.2: Anatomy of eye Note that 3 to 4 mm posterior to limbus is very close to
the front of the eye.
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2.2 Experimental Design Methods
Choice of Voluntary Eye Movement
In the previous sections, we already discussed a few physiological challenges that are
associated with human eyes, including variations in concentrations across different
parts of the eye, changes to eye composition with aging, multiple clearance routes,
etc. It’s important to keep those challenges in mind when selecting features of
interest to be included in the eye model design.
In terms of choice of eye movements, there are four types of basic eye movements,
as mentioned earlier: saccades movements, smooth pursuit movements, vergence
movements, and vestibule-ocular movements. Details about their respectivemotions
and functions were explained in the introduction section and will not be repeated.
Essentially, there are three major types of motions involved in all the movements:
rapid lateral motion, rotating motion, and slow lateral motion.
Consciously inducing voluntary eye movements could potentially agitate vitreous
humor in the eye. Further, this could facilitate fluid flow in the eye and thus
promote drug delivery to the back of the eye. In addition, since patients are likely
to experience great discomforts right after injection procedures, a good eye exercise
procedure would require patients to move their eyes minimally. Thus, the lateral eye
movement at a low frequency is the target eye motion in this study.
Lateral movement is essentially moving eyes horizontally back and forth between
left and right. Movement magnitude and frequency are usually based on voluntary
decisions. In this study, the lateral movement is determined to be 45 degree in its
sweep angle 1 cycle per second (1 Hz) for the movement frequency. (Figure 2.3)
This motion is slow enough for a post-surgery patient to perform in a comfortable
manner. Of course, it is possible to select a highermovement frequencywhichmeans
the patient will need to move his/her eye in a much faster manner. However, based
on our experimental observations, simply increasing the eye movement frequency
does not necessarily facilitate a better drug mixing outcome. Rather, factor such as
eye morphology plays a more critical role. We will discuss about it in more details
in the discussion section.
15
Figure 2.3: Desired voluntary lateral movement in this study (Picture (a) demon-
strates an eye looking to the left and the orange arrow indicates the center of the eye
globe in (a); Picture (b) demonstrates the eye looking to the right and the green arrow
indicates the center of the eye globe in (b); During this voluntary lateral movement,
the eye moves back and forth between left (a) and right (b) at 1 Hz. The sweep angle
is 45 degree, which is demonstrated in (c))
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Vitreous Humor Preparation
Our eye model was made from glass in the form of a 1-inch (24.5 mm) diameter
globe (Figure 2.4). Its size is the same as the average size of a human eye. As
the vitreous medium, the DI water and salt mixture (0.9% saline) was chosen. As
mentioned before, on one hand, this mixture resembles general eye properties among
older populations whose vitreous are more fluidic than gel-like; on the other hand,
for operations that involve vitrectomy, it’s a standard procedure for ophthalmologists
to replace patients’ vitreous with 0.9% saline. The saline solution was prepared in
a large bulk (1 L) and stored at room temperature overnight. This assumes that the
solution property is consistent across all the experiments. In addition, the bottle was
shaken well before each use to ensure an even distribution of salt in the solution.
(Kummer et al., 2007)
As the second choice for vitreous humor, glycerol and water were mixed at 1 to 5
ratios to study the viscosity effect on the fluid mixing pattern. Table 2.2 should be
revisited for material properties.
Figure 2.4: Eye model in our study Fabricated at Caltech glass shop. The diameter
is 1 inch.
Various Injection Sites of Eye Model
A typical intravitreal injection procedure performed by ophthalmologists in the clinic
as well as the modified protocol in our study is summarized in Table 2.3 below. The
detailed position of each injection site is demonstrated in Figure 2.5. As mentioned
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before, the side injection is the closest to an ophthalmologist’s injection behavior,
whereas the center and bottom injection positions are more in-depth.
Item Our Protocol Ophthalmologist’s Protocol
Needle 21 Gauge needle 27 Gauge or 30 Gauge needle
Injection dura-
tion/frequency
100 µl injection over the
course of 1 min 50 µl injection every 4 weeks
Injection site bottom, center, and side(Figure 10)
3 to 4 mm posterior to limbus,
avoid meridian horizon, target
the central region
Table 2.3: Intravitreal injection protocol performed in the clinic vs. modified
protocol in this study
Figure 2.5: Various injection sites (The orange arrow represents needle tip; the front
of the eye is labeled in (a) and will be the same for (b) and (c))
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Imaging Technique -Overview
Digital particle imaging velocimetry (DPIV) technique was used to quantitatively
map the fluid field. In summary, fluorescencematerials weremixedwith the solution
of interests to assist with flow visualization. A series of flow images were taken
during a visualization session and the resulting images were cross correlated using
commercial software PIV3CView (PIVTEC). Quantitative results such as velocity
field could thus be obtained.
To set up the equipments, as shown in Figure 2.6, convex lens was used to spread
the laser beam vertically so that the camera was visualizing only a thin sheet of the
entire globe. The laser beam was carefully calibrated to pass through the center of
the eye model. Essentially, flow profiles on a 2D plane of a 3D object were observed.
In our study, a 445-nm blue laser was used to illuminate the particle laden flow field
(laser model: Skye 100-mW handheld 445-nm focusable blue laser pointer with
dual lock). The flow images were captured by a camera with a resolution of 640 by
480 pixel (IPX-VGA210-L; 90 mm Tamron Lens, Saitama, Japan; Sony Alpha-7) at
10 frame per second (fps). The camera setting was adjusted using the free software,
LYNX GigE Application. A majority of the parameters were set at their default
values, with a few modifications summarized in Table 2.4.
There were two types of fluorescence materials used in this experiment: fluores-
cence particle and laser-induced fluorescence (LIF, which is a dye). Both materials
can be excited by a laser of a given wavelength. Mixing fluorescence particles
(manufactured by Kodak Company) with the solution of interests can mark the fluid
flowmotion. Fluid flow images were then captured and PIV analysis was performed
on the resulting images to obtain velocity profiles. These velocity profiles were later
analyzed for making particle pathlines visualizations. Using LIF (fluorescein) for
visualization allowed us to observe the dynamic mixing process in the eye model.
Solution that carries fluorescein was injected into the solution without fluorescein.
By quantitatively analyzing fluorescein light intensities, the amount of drugs that
reached the target issue at different time stamps was quantified.
Before a visualization, the two fluorescence materials were mixed with either 0.9%
saline or glycerol/water mixture. Fluorescence particles were carefully selected to
have the same density and diffusivity as the solution so the particle movements were
representative of flow motion. In this motion-driven study, fluorescence particles
manufactured by the Kodak company were selected since density of these particles
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were very close to 0.9% saline. Fluorescein was added to 0.9% saline or glyc-
erol/water mixture at the ratio of 1:50 (fluorescein to solution ratio). This assumes
that any possible changes to physical properties of the solution due to addition of
fluorescein were negligible.
Summary of PIV Visualization Set Up
In summary, there were a few major equipments to complete a PIV visualization
setup: a blue-violet laser (wavelength = 445 nm) for exciting fluorescence materials,
a convex lens to spread the laser beam into a laser sheet, a camera (IPX-VGA210-L)
for capturing flow images, an eye model, and a motor-magnet coupler to induce
lateral movements at a fixed pattern. (Figure 2.6 and 2.7)
Figure 2.6: Schematic Demonstration of PIV Visualization Setup (from left to right:
direction of rotation, the eye model mounted on top of a motor, a concave lens, and
a laser.)
After a visualization session, the resulting raw images were analyzed using PIVview
software (PIVtech, Gottingen, Germany) with the following parameters as summa-
rized in 2.4 below. The camera settings (LYNXGigEApplication) thatwere changed
from their default values are summarized in 2.5 below. The flow measurement was
valid up to approximately 1 mm/s, which was the velocity at which an object moved
one pixel during the exposure time.
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Figure 2.7: Actual PIV Visualization Setup (from left to right: motor-magnet
coupler with the eye model, a concave lens, and a laser)
Image Pair Offset 3
Window Size [Pixel] 32 by 32
Step Size [Pixel] 16 by 16
Fast Fourier Transform Correlation Standard
Maximum Displacement Test[Pixel] 10
Normalized Median Test (thresh) 5
Interrogation multi-pass
Table 2.4: Parameters used in PIVview software for Particle Image Velocimetry
(PIV) analysis
Exposure Time 10 fps
Shutter Time 5000
Table 2.5: Specified camera settings in LYNX GigE Application
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Motor-magnet coupler
Themotormagnet couplerwas composed of threemajor components: motor (Maxon
DC Motor EC 90 Flat Series), a 3D printed holder set for holding the eye model
and magnets, and four magnets. (Figure 2.8) The top part of the 3D printed holder
set held the eye model and was entirely immersed in a small fluid tank. Fluid that
was added into the tank was the same as the fluid that filled the eye model. This
ensured that both fluids had the same refractive index and thus no distortions when
laser beam passed through the curvature of the eye model.
The bottom part of the holder set sat on top of the motor, which was controlled
by EPOS motor controller and LabVIEW. LabVIEW program sent out signals to
control the movement of the motor, which also drove the motion of the bottom part
of the holder set. (Again, for lateral movements in our study: 45 degree sweep angle
at 1 Hz.) The two magnets that were fixed on the bottom holder drove the motions
of the two magnets that were fixed on the top holder, and thus the movement of the
eye model. The actual motor movement was recorded throughout the experiment.
This allowed for tracking and checking the actual motor trajectory during and after
each experiment (Figure 2.9).
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Figure 2.8: Motor-Magnet Coupler Setup (The four orange columes indicate the
positions of the four magnets; the eye model (sphere) sits on the top is immersed in
a water tank.
Figure 2.9: Example of a plot of the actual motor trajectory (5 cycles rotations)
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Drug Delivery Method
As mentioned earlier, LIF could assist with the observations of drug mixing profile
in the eye model. Fluorescein/0.9% Saline mixture of 100 microliters were slowly
injected into the eye model that was filled with 0.9% saline at the desired injection
spot using a syringe pump (Harvard Apparatus). The entire injection process took
about 1 min in total, which was very slow and did not cause the drug to splash
inside the eye model. This injection process reproduced the intravitreal injection
procedure of injecting microliter-scale of drugs (fluorescein/saline mixture in our
study) into the vitreous humor (saline in our study).
24
2.3 Results
Velocity Vector Plots
Figure 2.10 shows a typical image captured during a PIV visualization session. The
white dots are fluorescence particles excited by the 445-nm blue laser light. Note
that we wanted to observe fluid motions after the lateral movement stopped. This
could help with understanding the duration of mixing after each set of movements.
Therefore, during a PIV visualization session, image capturing began before the
eye model started to rotate and stopped after the fluid motion completely decayed.
However, during a PIV analysis session, only images taken after the eye rotation
stopped were analyzed. This also ensured that PIV analysis was performed on the
same 2D plane because the visualization plane kept switching when the eye model
was moving. In our study, we made comparisons between 5 cycle rotations (rotating
a full cycle for five times) versus 10 cycle rotations (rotating a full cycle for ten
times).
The average velocity vector plot obtained from a PIV analysis is shown in Figure
2.11. It was obvious to observe from this vector plot that four circulations were
formed during the rotation and still sustained after the rotation stopped. To un-
derstand whether the duration that circulations sustained was different between less
movements (5 cycles) and more movements (10 cycles), a sequence of vorticity plots
was made. Figure 2.12 summarized the first sets of vorticity plots (5 cycles on the
left and 10 cycles on the right), which were taken right after the rotation stopped. In
these plots, vorticity appeared to be stronger after 10 cycles movements as compared
with 5 cycles movements. The circulations also sustained for a bit longer after 10
cycles movements, although this information was hard to show in Figure 2.12. It
was also worth noting that circulations sustained for quite a short duration in both
cases: approximately 5 seconds after 5 cycles movements and 10 seconds after 10
cycles movements.
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Figure 2.10: Example of an image captured during a PIV visualization session
Figure 2.11: Average Velocity Field Obtained from PIV analysis (5 cycles)
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Figure 2.12: First Sets of Vorticity Plots: 5 cycles vs 10 cycles (Note these were
taken right after the movements stopped)
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Particle Pathline Visualization (0.9% Saline)
Particle pathline visualization is very helpful for understanding the actual parti-
cle trajectory. After performing PIV analysis on raw images using the software
PIV3CView, files containing flow field information were obtained. Because the
flow images were taken at a programmed rate of 10 frames per second, these files
were also ordered in a sequential manner. Important flow information contained in
these files includes physical coordinate (x,y), velocity components (x,y), velocity
gradient (du/dx, du/dy, dv/dx, dv/dy), and vorticity component. (Figure 2.13)
Using these velocity field information, the Lagrangian path of fluid flow can be
tracked to create a pathline visualization using MATLAB. At first, locations of
particles of interests were defined to obtain and plot the initial position. Then the
files containing velocity field were referred at each instance of time to plot the
following positions. This same process was repeated over a certain period of time.
This is essentially the same as overlaying a sequence of actual particle images onto
a single image.
A detailed explanation of the algorithm is shown in Figure 2.14. In Figure 2.14, U
is the velocity, which is a function of position (x) and time (t); delta t is the time
interval between two adjacent images captured; T0 is the initial time, T1 = T0 + δt,
and so on. After determining the initial position, the next position at T1 is calculated
based on the velocity field of the previous position (which is U(x0, t0) in this case).
This gives the particle position at T1. The same procedure is used at successive
time steps to generate the pathline field for the following positions and that’s how
we obtain the pathline.
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Figure 2.13: PIV analysis can generate a series of files that contain flow property
information in a sequential manner
Figure 2.14: Detailed explanation of pathline visualization algorithms (Blue circles
indicates particles at different instances of time.)
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An example of such pathline visualization is shown in Figure 2.15, which demon-
strates the particle trajectories in a total of 8 seconds after 10 cycles lateral move-
ments. Again, the particle pathline tracking begins after the rotation stops and ends
when circulations completely decay.
As it is highlighted in Figure 2.16, there are four circulations in the flow and one
in each quadrant, which is consistent with the observations from the vorticity plots
shown in Figure 2.12. Another important takeaway message from the pathline
visualization and vorticity plots is that the initial position of the particle is very
likely to affect the final position of the particle. This insight will be discussed
further in the discussion section.
Figure 2.15: Particle pathline demonstration (The beginning of the time is color-
coded in dark blue, then green, and finally light blue)
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Figure 2.16: Four circulations and one in each quadrant
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LIF Visualization – Different Injection Sites
To understand whether injecting drugs at different sites can make a difference to
the final drug mixing profile, a LIF visualization experiment was performed. Drugs
(mixture of 0.9% saline and fluorescein) were injected at the bottom, center, and side
locations of the eye model. In this set of experiments, the eye model went through
a series of 10 cycles lateral movements intermittently: after the initial injection,
the eye model was rotated for 10 cycles. The magnitude of drug mixing was then
observed and recorded by the camera before another 10 cycles of rotations was
performed. This process was repeated until drugs were well mixed in the entire
chamber. The resulting images were summarized in Figure 2.17. By examining the
images carefully, it was obvious to see that center injection took the shortest amount
of time as well as the least amount of movements for the drug to mix well in the eye.
Bottom injection and side injection took a longer duration and more movements to
achieve complete drug mixing in the eye.
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Figure 2.17: Dye visualization images from varying injection sites (From top to
bottom: bottom injection, center injection, and side injection)
33
LIF Visualization – Viscosity Effects
As mentioned in the background section, human eye’s vitreous humor property
varies among different individual and changes as a person ages. To study the
effect of solution property on the mixing process in the eye, glycerol and water are
mixed together to generate a series of solutions with various viscosity and density.
Therefore, in this set of experiments, the glycerol/water mixture was used in place of
0.9% saline to help with understanding whether lateral movements can also promote
drugs mixing in a vitreous humor that is more gel-like.
After injecting drugs (glycerol/water/fluorescein mixture) into the eye model (filled
with glycerol/water mixture), 10 cycles of lateral movements were introduced to the
eye model in the "lateral rotation" experiment. A flow image was taken at every
10 mins for 30 mins in total. Overall, observations were made at the following five
instances of time: the moment right after injection, the moment right after lateral
movements stop, 10 mins after injection, 20 mins after injection, and 30 mins after
injection. The same process was repeated in the "no rotation" experiment, although
no rotation was involved in this process. Therefore, the second image was taken at
1 min after injection instead. (Figure 2.18)
Particle concentration is a good indicator for the mixing process, which can be
reflected by the pixel intensity. In geohydrology, people use fluorescein in situations
where there is insufficient lighting but precise quantitative data is required. The
intensity of visible spectrum fluorescence after excitation by a certain spectrum
light is measured by a fluorimeter to identify the presence and the amount of specific
molecules in a medium. Taking the same idea, in our quantification process, the
pixel intensity (grayscale value) was used to indicate the concentration of drug
(glycerol/water/fluorescein mixture)
Pixel intensity was measured using the open source software image J. The grayscale
reading function in Image J can quantify the maximum grayscale value in a defined
region. As demonstrated in Figure 2.19, the area of interest was defined first
so the program only calculated pixel intensity within the defined region. The
location of this defined region corresponds to the location of macula in a human eye.
Quantification results are summarized in Figure 2.19. Apparently, for amore viscous
vitreous humor, introducing lateral movements can still promote drug mixing in the
eye.
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Figure 2.18: Dye visualization images (It shows observations over the course of
30 mins. Image sequence is taken immediately after injection, the moment after
rotation stops, and every 10 mins afterwards.)
Figure 2.19: Fluorescent particle concentration reaching the target tissue (This
quantifies the amount of fluorescein (drugs) that reaches the target tissue over the
course of 30 mins after 10 cycles of lateral rotation)
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Particle Pathline Visualization (glycerol/water mixture)
Results from previous sections show that intermittently introduced lateral rotations
can facilitate a faster drug mixing in the eye. We also learned that lateral movements
can be helpful even with vitreous humor of higher viscosity/density. However, in
the glycerol/water mixture LIF visualization images, the four circulations weren’t
observed. Therefore, this inspired us to repeat the flow visualization (with fluores-
cent particles) that has been done with 0.9% saline, although with glycerol/water
(1:5) mixture this time.
PIV visualization and PIV analysis were performed for the following three time
intervals: after the first 10 cycles of lateral movements, after another 10 cycles of
lateral movements, and finally after a final 200 cycles of lateral movements. The
resulting raw images were then analyzed following the same PIV analysis procedures
and particle pathlines were visualized in MATLAB. The resulting particle pathline
visualizations were summarized in Figure 2.20, Figure 2.21, and Figure 2.22 below.
Similarly, the initial positions of particles were color-coded in dark blue, then green,
and finally light blue. The entire duration of particle tracking was 10 seconds, which
was consistent with the analysis with 0.9% saline. During the actual experiments, no
obvious circulation was observed visually. Not surprisingly, these particles didn’t
move as much as indicated in the pathline visualization results below: it’s even hard
to tell a difference between particle pathlines after 10 cycles of movements and after
200 of cycles movements.
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Figure 2.20: Particle pathline tracking after 10 cycles of rotation (glycerol/water
mixture)
Figure 2.21: Particle pathline tracking after a second 10 cycles of rotation (obser-
vation continued from2.20
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Figure 2.22: Particle pathline tracking after 200 continuous rotations (Using glyc-
erol/water mixture)
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2.4 Discussion
Dye visualization (varying injection sites)
The dye visualization results summarized in the previous sections show that center
injection takes the shortest amount of time as well as the least amount of movement
to mix the drug well in the eye. The bottom injection and side injection take a
similar amount of movement and duration to achieve complete drug mixing in the
eye. This observation could be explained further by comparing it with the results
from particle pathline visualization.
We learned that lateral movements can induce four circulations. To make direct
comparison, particles in the three regions of interests are highlighted in Figure 2.23
below. It is obvious that particles in the side and bottom regions are “trapped”
around their initial locations. Particles that are initially in the center region have
more flexibility to move towards other regions. As it was described earlier, in the
clinical setting ophthalmologists tend to inject drugs at a location that is very close
to the front of the eye. This might not be an optimal spot because it directly puts
drug at a “side” location, which might not be so helpful in facilitating drug deliveries
to the back of the eye.
Since all the previous observations of fluid patterns are made after the rotation stops,
and these circulations apparently don’t sustain for long enough. It has triggered our
curiosity to explore an imaginary scenario where the circulations don’t decay, and
this could be achieved easily via MATLAB simulation. To simulate the case where
circulations don’t decay, the first fluid velocity field from the moment right after
lateral movement stops was taken to be projected for the following instances of time.
In this way, it was assumed that the velocity field with the strongest circulation
was sustained (Figure 2.24). The simulation result was summarized in Figure 2.25.
Similar observations can be made from this simulation result: particles that start
from the center regions have more freedom to move towards other regions, whereas
particles in the side/bottom regions tend to stay.
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Figure 2.23: Highlighted particles in the center, bottom, and side regions. (Pink
color labels particles in the center region; blue color labels particles in the side and
bottom regions)
Figure 2.24: Demonstration of the simulation methodology (The first velocity field
is projected throughout the rest of the instances of time.)
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Figure 2.25: Particle pathline if the circulation doesn’t decay (The velocity field is
taken from the first instance of time from the PIV analysis results; particle pathline
starts from dark blue to green and finally light blue.)
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Variations in particle pathline tracking results (0.9% saline vs glycerol/water
mixture) and the implication for the choice of eye movement frequencies
Asmentioned before, four circulations were observed after introducing lateral move-
ments to 0.9% saline but the same mixing pattern wasn’t observed in the glyc-
erol/water mixture. This discrepancy is possibly an effect of Reynolds number.
Reynolds number describes the convection process over diffusion process in the
flow motion. If Reynolds number is large, the convection process dominates over
the diffusion process. Reynolds number can be calculated as
Re = ρUD/µ
where ρ is the density of fluid, U is the velocity of flow, D is the characteristic
length, and µ is the dynamic viscosity.
Using the material properties as indicated in Table 2.2, Reynolds number is around
400 in the 0.9% saline case, whereas in the glycerol/water mixture case, Reynolds
number is around 200 or smaller. There is likely a transition point in the range 200
< Re< 400, which determines whether the circulations can be turned on. Since ρ,
µ, and D varies among different individuals and these parameters also changes over
time to the same person with aging process, it’s not certain that lateral movements
of the eye can facilitate drug mixing for everyone, although with higher rotation
speed (U), Reynolds number is higher and a possibly better mixing effect may be
achievable. However, the feasibility in real life requires future in-depth studies. After
all, the morphology-related factors (ρ, µ, and D) play stronger effects. Therefore,
if a patient has a very viscous vitreous humor, simply increasing the eye movement
frequency can hardly affect the mixing outcome.
42
Summary
Although applying lateral movements can introduce convective flow into the vitreous
chamber and facilitate improved drug mixing, it might not be an optimal solution
for the following two reasons:
1) The overall circulation effects induced by lateral movements don’t sustain for long
enough to ensure a continuous mixing;
2) Whether the circulations can be turned on or not depends largely on each indi-
vidual’s eye properties.
Since our goal is to achieve good drug mixings with minimal efforts required for the
patients, we need to look for a better method. This is where thermal-driven method
comes in.
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C h a p t e r 3
THERMAL EFFECTS ON FLUID MIXING IN THE EYE
3.1 Introduction
Background Introduction
This part of the study explores thermal effects on promoting drug mixing in the eye.
Specifically, the following three factors are investigated to understand their effects
on thermally promoting drug mixing in the eye:
1) varying temperature difference,
2) varying heating position,
and 3) varying density difference between the drug and vitreous humor.
As mentioned before, there hasn’t been much study on drug mixing in the eye in
the past. Limitations are primarily due to two reasons. On one hand, anatomy and
physical properties of living animal vitreous structure are neither fully understood
nor representative; on the other hand, since too many factors are involved and many
parameters are unknown, numerical simulation is difficult.
Therefore, in our study, we approach the topic from the experimental perspective.
The study outcomes will not only be meaningful for achieving fundamental under-
standings of fluid dynamics in the eyes, but also be helpful for ophthalmologists to
optimize operation procedures for improved patient experience.
Variables of interests
The same eye model from the previous study was used in this part. To determine
what temperature differences to study, it is necessary to understand the heat tolerance
of the human subject first. For human beings, eyes are sensitive and thus cannot
endure high temperatures for a long time. Given that the temperature limit for a
human being to feel pain is 10 Celsius above body temperature, it makes sense to
pick in the range of 0 – 10 Celsius temperature difference. Therefore, 5 Celsius and
10 Celsius temperature difference are selected to apply between the eye model and
the heat source.
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In addition, heating position is another variable to study. Different fluid motions are
stimulated by placing the heat source at different positions around the eye. Some
might be more aggressive than others. Therefore, this study outcome can also
promote the idea of precision heating, making it possible to achieve optimal fluid
mixing results without having to introduce too much temperature change to the eye.
In this case, five heating positions are defined as marked in Figure 3.1. Note that
the heads-up position simulates the scenario of a person who lays on the chair with
his/her head facing upwards, whereas the heads-down position means the opposite.
In the previous study, drug (fluorescein/solution of interests mixture) is added to
the vitreous solution (solution of interests) of the same density/viscosity. However,
in this study, the effects of introducing density/viscosity difference between the
injected drug and the vitreous are studied. This can give us a more realistic angle
in understanding how drugs are delivered in various environments. More details
regarding solution preparations are explained in the following sections.
Figure 3.1: Five heating positions around the eye (Upper, center, and lower positions
are defined in terms of a person sitting upright; the heads-up position simulates the
scenario of a person who lays on the chair with his/her head facing upwards, whereas
the heads-down position means the opposite.
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3.2 Materials and Methods
Vitreous Humor Preparation
To prepare for liquid that goes into the container, glycerol and water at various water-
to-glycerol ratios (5:1, 5:2, and 10:1 respectively) were made in bulk. Each set of
mixtures was placed in the room temperature for more than 48 hours to ensure a
consistent initial temperature. It is worth noting that glycerol/water (1:5)mixture has
physical properties (density and viscosity) that are most similar to vitreous humor
in the eye. Table 2.2 should be revisited to make reference to the water/glycerol
mixtures that are used in this study and their respective physical properties.
Heat Source Fabrication
The heat source for inducing temperature gradient was composed of a steel stick,
a polyimide flexible heater (OMEGA Engineering, KHLVA-0502), an aluminum
piece, and a voltage box. The aluminum piece was made at the Caltech GALCIT
machine shop. The curvature was customized and tested a few times until the
aluminum piece could make a good contact area with the existing eye model. The
effective contact area was approximately 5 mm by 5 mm. A demonstration of the
entire heating element assembly is shown in Figure 3.2 below. After successfully
putting the parts together, the heating element assemblywas then completely covered
by black tape. This ensured that the metal part would not interfere with the laser
path during a visualization session. (Figure 3.3)
A calibration experiment was designed to obtain a voltage-temperature relationship.
This facilitated an indirect but accurate temperature control via voltage reading.
During the calibration process, voltage input was increased incrementally by 2
Volts at a time. Temperature readings were obtained using a digital thermometer.
After each voltage adjustment was made, a temperature reading was recorded after
it became stabilized for at least 10 mins. Temperatures at two locations were
measured, denoted as A and B in Figure 3.2. The calibration process was repeated
a few times to ensure its accuracy. This voltage-temperature curved was referenced
for temperature control throughout this study.
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Figure 3.2: Key components of the heating source (There are three major com-
ponents: the solid blue part represents the steel stick; the yellow part represents
polyimide flexible heater which sits on top of the steel stick, the two cables are
connected to the power box, and the hollow blue part represents the customized
aluminum piece.)
Figure 3.3: Heating element assembly wrapped with black tapes
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Figure 3.4: Heating element at the “center” heating location
PIV Visualization
Same imaging techniques were used in this study. Therefore, most of the PIV
visualization procedures were the same as before, and thus the same set-up details
would not be repeated in this section. For fluorescence particles, silver coated
fluorescence particles were used in place of Kodak fluorescence particles. The
silver coated fluorescence particles were heavier. To prepare for solutions for PIV
visualizations, a spoonful of silver coated fluorescence particles was mixed with the
solution of interests. After these particles were settled and stratified in the solution,
only the middle layer was captured for use in PIV visualization. (Figure 3.5) The
flow profile was observed and captured at 10 frame per second (fps) for a duration
of 10 mins after the heat source was applied.
For laser induced fluorescence visualization (FIL), fluorescein was first dissolved
in water and then mixed with solution of interests at 1:50 ratio (fluorescein to
solution of interests = 1:50). Since density and viscosity of glycerol/water (1:5)
mixture is the most similar to those of human vitreous humor’s, glycerol/water (1:5)
mixture is the primary working solution to fill up the eye model. Glycerol/water
(1:10) mixture and glycerol/water (2:5) mixture were mixed with fluorescein at 1:50
(fluorescein: solution) ratio. Adding glycerol/water/fluorescein (2:5) mixture to the
eye model simulates the process of adding drug that is heavier and more viscous
than the vitreous humor to the eye; whereas adding glycerol/water/fluorescein (1:10)
mixture to the eye model simulates the process of adding a lighter and less viscous
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drug to the eye.
As mentioned before, pixel intensity is correlated with drug (glycerol/water/ fluo-
rescein mixture) concentration. Therefore, to quantify the amount of drug (glyc-
erol/water/fluorescein mixture) that have entered target treatment region, the image
tool in MATLAB was used for pixel intensity quantification. MATLAB was used in
place of ImageJ here because it facilitated mass processing of thousands of images.
Figure 3.6 below shows a screenshot of imaging processing using the image tool
in MATLAB. The area of interest was defined as a 5-pixel by 20-pixel rectangle
located near the center of the eye model on the right side. The location of this
region corresponds to the actual position of the macula, which is the desired AMD
treatment spot in the eye. The size and location of this region were kept the same
throughout all image quantifications.
Figure 3.5: Stratified silver-coated particles/glycerol/water mixture The heaviest
particles stay at the bottom whereas the lightest ones float in the top region. Only
the middle portion is suitable for visualization purpose as particles in this region
share approximately the same density with the glycerol/water mixture.
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Figure 3.6: Pixel intensity quantification using the image tool in MATLAB (The
purple box highlighted in the picture on the right defines the area of interests for
pixel intensity quantification. When fluorescein is excited by the laser, it becomes
bright/white in the image. In this image, fluorescein is distributed in the top right
region.)
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Pathline Visualizations Using ImageJ
The idea of using ImageJ to visualize particle pathline is the same as usingMATLAB
programming to track particle pathlines. The “Grouped Z Project” tool in ImageJ
allows for overlaying a particle image sequence onto a single image (z-projection),
and the overall range of time of the image sequence can also be determined. The
total duration of each flow visualization session was 10 mins at 10 fps. Therefore,
a total of 6,000 images were taken for each flow visualization session. Using the
“Grouped Z Project” tool, these 6,000 images were segregated into 60 groups. Then
a z-projection was performed on the 100 images in each group. The result was a
new stack of images, one slice for each group.
CFD Simulation Using FEATool Multiphysics
Acomputation studywas conductedwith the aid of FEAToolMultiphysics/MATLAB.
The fluid has thermal diffusivity α and viscosity ν. Rayleigh number for this flow
is defined as
Ra =
gβδT x3
αν
= 8300
for water/glycerol (5:1) mixture at δT= 10 Celsius, and Prandtl number is defined as
Pr =
Cpµ
k
= 13.48
for water/glycerol (5:1) mixture. Note that δT is the temperature difference between
the heat source and the eye model. All lengths are non-dimensionalized with respect
to D, the diameter of eye model; all velocities with respect to α/D ; time with respect
to D2/α; vorticity with respect to α/D2 temperature with respect to δT . The study
object was modeled as a two-dimensional viscous Boussinesq fluid in a circular
domain, and the equations for numerical modeling are listed below: ((Moore and
Davis, 1984))
∂U
∂X
+
∂V
∂Y
= 0 (3.1)
∂U
∂τ
+U
∂U
∂X
+ V
∂U
∂Y
= − ∂P
∂X
+ Pr(∂
2U
∂X2
+
∂2U
∂Y2
) (3.2)
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∂V
∂τ
+U
∂V
∂X
+ V
∂V
∂Y
= −∂P
∂Y
+ Pr( ∂
2V
∂X2
+
∂2V
∂Y2
) + RaPrT (3.3)
∂T
∂τ
+U
∂T
∂X
+ V
∂T
∂Y
=
∂2T
∂X2
+
∂2T
∂Y2
(3.4)
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3.3 Results
Pathline Visualization Using Image J
This section summarizes pathline visualization results using Image J. The algorithm
was explained in the previous section. Flow visualization was performed on the
following six cases:
1) 5-degree temperature difference (center position heating, Figure 3.7),
2) 10-degree temperature difference (center position heating, Figure 3.8),
3) 10-degree temperature difference (lower position heating, Figure 3.9),
4) 10-degree temperature difference (upper position heating, Figure 3.10),
5) 10-degree temperature difference (heads-up heating, Figure 3.11),
and 6) 10-degree temperature difference (heads-down heating, Figure 3.12).
During each session, a total of 6,000 images were taken. After performing a z-
projection, there were 60 slices of 100 images in each slice for every case. Only one
slice from each case was selected to be included in this section, and these slices are
all captured during 5 mins to 5 mins and 10 second in each experiment. In addition,
a slice of 100 images taken before the heating source was applied was also included
as a control case. (Figure 3.13)
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Figure 3.7: Pathline visualization from 5-celsius temperature difference (center
heating) These 100 images were taken from 5 mins to 5 mins and 10 secs. Note that
most of the flow behavior was happening on the left half of the eye model.
Figure 3.8: Pathline visualization from 10-celsius temperature difference (center
heating) These 100 images were taken from 5 mins to 5 mins and 10 secs. Note that
the flow was stronger compared with the one in Figure 3.7a, although circulation
was relatively weak at the very bottom of the eye model.
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Figure 3.9: Pathline visualization from 10-celsius temperature difference (lower
heating) These 100 images were taken from 5 mins to 5 mins and 10 secs. Note that
circulations were fully activated across all regions in the eye model.
Figure 3.10: Pathline visualization from 10- Celsius temperature difference (upper
heating) These 100 images were taken from 5 mins to 5 mins and 10 secs. Note that
most of the flow behavior was happening on the top part of the eye model.
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Figure 3.11: Pathline visualization from 10- Celsius temperature difference (heads-
up heating) These 100 images were taken from 5 mins to 5 mins and 10 secs. Note
that the overall flow behavior was not quite strong.
Figure 3.12: Pathline visualization from 10-Celsius temperature difference (heads-
down heating) These 100 images were taken from 5 mins to 5 mins and 10 secs.
Note that the flow behavior was very strong. It’s very hard to describe a distinct
pattern from this image.
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Figure 3.13: Pathline visualization before the heat source was applied. These 100
images were taken for a duration of 10 seconds.
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Apparently, a greater temperature difference can activate stronger circulations in the
eye model. For a person who’s standing/sitting in the upright position, heating from
the lower position can activate mixing in the entire eye model, whereas center and
upper heating can only activate partial mixing in the eye model. For a person who’s
laying down on the chair with his/her head facing up, placing a heat source on top of
his/her eyes doesn’t seem to help with mixing, whereas having his/her head facing
down instead can possibly induce very aggressive mixings in his/her eyes. The same
conclusion can be drawn from quantification of flow circulation as shown in figure
3.14. Clearly, both heating from lower position at = 10 Celsius and heating at the
heads-down position induce strong rotational motions of the flow in the eye model.
In summary, lower heating for someone in the upright position as well as heating
from a heads-down position can be very helpful in achieving our goal to facilitate
efficient drug mixing in the eye after an intravitreal injection.
Figure 3.14: Circulation represents the rotational motion of flow in the eye model.
Here, we took the absolute value of circulation in each case.
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Pathline Visualization Using MATLAB
Vorticity plots can help us understand the intensity of mixing. Regions of high
vorticity magnitude typically correspond to regions of stronger shear or fluid cir-
culation. The sign of the vorticity provides the direction of fluid circulation. The
average magnitude of vorticity in each case over the course of 5 seconds (from
5 mins to 5 mins and 5 seconds) is summarized in the vorticity plot below. In
comparison, particle pathline tracking for the same duration was generated using
MATLAB. (Figure 3.15) The algorithm for generating pathline visualization using
MATLAB was described in the previous section. This pathline tracking is slightly
different from the pathline visualization using ImageJ since the resulting images
are more explicit in showing the particle trajectories. However, the fundamental
idea is the same. Overall, observations obtained from vorticity plot and pathline
visualization are consistent with the conclusions in the previous section.
Figure 3.15: An example of pathline visualization using MATLAB. (The position
of heat source is marked in the plot.)
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Figure 3.16: Average vorticity plot from δT = 5 Celsius (center heating)
Figure 3.17: Pathline visualization from δT = 5 Celsius (center heating)
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Figure 3.18: Average vorticity plot from δT = 10 Celsius (center heating)
Figure 3.19: Pathline visualization from δT = 10 Celsius (center heating)
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Figure 3.20: Average vorticity plot from δT = 10 Celsius (lower heating)
Figure 3.21: Pathline visualization from δT = 10 Celsius (lower heating)
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Figure 3.22: Average vorticity plot from δT = 10 Celsius (upper heating)
Figure 3.23: Pathline visualization from δT = 10 Celsius (upper heating)
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Figure 3.24: Average vorticity plot from δT = 10 Celsius (heads-up)
Figure 3.25: Pathline visualization from δT = 10 Celsius (heads-up)
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Figure 3.26: Average vorticity plot from δT = 10 Celsius (heads-down)
Figure 3.27: Pathline visualization from δT = 10 Celsius (heads-down)
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To facilitate a better understanding of the impact of varying temperature gradient
and heating position on the trajectory of individual particles, data obtained from
PIV analysis were analyzed in MATLAB and variables including u, v, x, y, and t
were coordinated to track individual particle behavior. Here, three scenarios were
compared: δT = 5Celsius center heating, δT = 10Celsius center heating, and
δT = 10Celsius lower heating. The results are summarized in Figure 3.28,3.29,3.30.
For a 2D analysis, it was assumed that a disk-shaped drug (radius = 0.4 cm) was
injected into the center plane of the vitreous chamber (radius = 11 cm). The initial
position of the drug in all three scenarios were kept the same and the goal was to
observe the time duration it took for the particle to reach the back of the eye during
the 10 mins heating process. The position of macula is in the back of the eye, which
corresponds to the middle section of the right-side boundary of the circular domain.
Since particles tend to move along the curvature once they are near the boundary,
we claim that the particle delivery is successful as soon as it reaches the boundary
on the right.
As it is demonstrated in Figure 3.28, 3.29, and 3.30, heating from a lower position at
δT = 10Celsius helped the particle to deliver within the shortest time (less than 200
seconds); heating from the center position at δT = 10Celsius trapped the particle
in a flow circulation during the first 400 seconds but the particle could delivery
successfully by the end of 600 seconds (10 mins); heating from the center position
at δT = 5Celsius was not helpful. The results are consistent with observations from
the previous pathline visualizations.
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Figure 3.28: Individual particle tracking for δT = 5Celsius, heating from the
center. The blue circle indicates the initial position of the particle; dark blue line
indicates particle movements during the first 200 seconds; green line indicates
particle movements during the second 200 seconds, and light blue line indicates
particle movements during the last 200 seconds. Heating position is marked in red
along the circular boundary.
Figure 3.29: Individual particle tracking for δT = 10Celsius, heating from the
center. The blue circle indicates the initial position of the particle; dark blue line
indicates particle movements during the first 200 seconds; green line indicates
particle movements during the second 200 seconds, and light blue line indicates
particle movements during the last 200 seconds. Heating position is marked in red
along the circular boundary.
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Figure 3.30: Individual particle tracking for for δT = 10Celsius, heating from the
lower position. The blue circle indicates the initial position of the particle; dark blue
line indicates particle movements during the first 200 seconds; green line indicates
particle movements during the second 200 seconds, and light blue line indicates
particle movements during the last 200 seconds. Heating position is marked in red
along the circular boundary.
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Quantification Results from LIF Visualization
To simulate the actual drug delivery process, LIF visualization was performed on
the following four cases:
1) Adding water/glycerol (5:2) drug mixture into water/glycerol (5:1) vitreous mix-
ture with center heating; (Figure 3.31 and 3.32)
2) Adding water/glycerol (5:2) drug mixture into water/glycerol (5:1) vitreous mix-
ture with lower heating; (Figure 3.33 and 3.34)
3) Adding water/glycerol (10:1) drug mixture into water/glycerol (5:1) vitreous mix-
ture with center heating; Figure 3.35 and 3.36)
4) adding water/glycerol (10:1) drug mixture into water/glycerol (5:1) vitreous mix-
ture with lower heating; Figure 3.37 and 3.38)
The maximum pixel intensity reading from each heating method is summarized in
Table 3.1. In summary, when drugs are heavier than the vitreous humor, heating
from the center is not so helpful for facilitating drug mixing in the eye. When
drugs are lighter than the vitreous humor, both center heating and lower heating are
useful and can induce strong drug mixing profiles within an hour. Lower heating
can activate strong drug mixing regardless of the density of the drug.
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Figure 3.31: Pixel Intensity Quantification Results from LIF Visualization: Heavier
drug and center heating during the first 10 mins.
Figure 3.32: Pixel Intensity Quantification Results from LIF Visualization: Heavier
drug and center heating during the last 10 mins.
70
Figure 3.33: Pixel Intensity Quantification Results from LIF Visualization: Heavier
drug and lower heating during the first 10 mins.
Figure 3.34: Pixel Intensity Quantification Results from LIF Visualization: Heavier
drug and lower heating during the last 10 mins.
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Figure 3.35: Pixel Intensity Quantification Results from LIF Visualization: Lighter
drug and center heating during the first 10 mins.
Figure 3.36: Pixel Intensity Quantification Results from LIF Visualization: Lighter
drug and center heating during the last 10 mins.
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Figure 3.37: Pixel Intensity Quantification Results from LIF Visualization: Lighter
drug and lower heating during the first 10 mins.
Figure 3.38: Pixel Intensity Quantification Results from LIF Visualization: Lighter
drug and lower heating during the last 10 mins.
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Heating Method 0-10 mins 40-50mins
Lighter drug, center heating 0 In the range of 1.4-2.6
Lighter drug, lower heating 0 In the range of 0.4-2.4
Heavier drug, center heating 0 0
Heavier drug, lower heating 0 In the range of 0.5-3
Table 3.1: Maximum Pixel Intensity in Each Heating Method
ComputationalAnalysis (MATLAB/FEAToolMultiphysics) (Tool:FEAToolMul-
tiphysics v1.11)
Both velocity profiles from experimental measurements and simulations are sum-
marized in Figure 3.39 to 3.74 below. Velocity profiles at t = 2.5 min, 5 min, and
7.5 min from experimental measurements as well as T = 0.009, 0.0185, and 0.037
(equivalent as t = 45 s, 1.5 min, and 3 min) from numerical simulations are dis-
played. All the variables were non-dimensionalized with respect to the parameters
described in the material and method section. Clearly, flow profile developed and
became stabilizedmuch faster in numerical simulations compared with experiments.
This was because the experiments were conducted in 3D and numerical simulations
were performed in 2D. However, the results are consistent in either method in terms
of the velocity magnitude, flow direction, and movements of the center of the cir-
culation. Therefore, numerical simulation method that was developed in this study
could potentially be used in place of experiments for any future studies.
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Figure 3.39: δT = 5Celsius center heating (experimental results) at 2.5 min
Figure 3.40: δT = 5Celsius center heating (experimental results) at 5 min
Figure 3.41: δT = 5Celsius center heating (experimental results) at 7.5 min
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Figure 3.42: δT = 5Celsius center heating (simulation results) at t=0.009
Figure 3.43: δT = 5Celsius center heating (simulation results) at t= 0.0185
Figure 3.44: δT = 5Celsius center heating (simulation results) at t = 0.037
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Figure 3.45: δT = 10Celsius center heating (experimental results) at 2.5 min
Figure 3.46: δT = 10Celsius center heating (experimental results) at 5 min
Figure 3.47: δT = 10Celsius center heating (experimental results) at 7.5 min
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Figure 3.48: δT = 10Celsius center heating (simulation results) at t=0.0009
Figure 3.49: δT = 10Celsius center heating (simulation results) at t=0.00185
Figure 3.50: δT = 10Celsius center heating (simulation results) at t=0.0037
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Figure 3.51: δT = 10Celsius lower heating (experimental results) at 2.5 min
Figure 3.52: δT = 10Celsius lower heating (experimental results) at 5 min
Figure 3.53: δT = 10Celsius lower heating (experimental results) at 7.5 min
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Figure 3.54: δT = 10Celsius lower heating (simulation results) at t=0.0009
Figure 3.55: δT = 10Celsius lower heating (simulation results) at t=0.00185
Figure 3.56: δT = 10Celsius lower heating (simulation results) at t=0.0037
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Figure 3.57: δT = 10Celsius upper heating (experimental results) at 2.5 min
Figure 3.58: δT = 10Celsius upper heating (experimental results) at 5 min
Figure 3.59: δT = 10Celsius upper heating (experimental results) at 7.5 min
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Figure 3.60: δT = 10Celsius upper heating (simulation results) at t=0.009
Figure 3.61: δT = 10Celsius upper heating (simulation results) at t=0.0185
Figure 3.62: δT = 10Celsius upper heating (simulation results) at t=0.037
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Figure 3.63: δT = 10Celsius heads-down heating (experimental results) at 2.5 min
Figure 3.64: δT = 10Celsius heads-down heating (experimental results) at 5 min
Figure 3.65: δT = 10Celsius heads-down heating (experimental results) at 7.5 min
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Figure 3.66: δT = 10Celsius heads-down heating (simulation results) at t = 0.009
Figure 3.67: δT = 10Celsius heads-down heating (simulation results) at t = 0.0185
Figure 3.68: δT = 10Celsius heads-down heating (simulation results) at t = 0.037
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Figure 3.69: δT = 10Celsius heads-up heating (experimental results) at 2.5 min
Figure 3.70: δT = 10Celsius heads-up heating (experimental results) at 5 min
Figure 3.71: δT = 10Celsius heads-up heating (experimental results) at 7.5 min
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Figure 3.72: δT = 10Celsius heads-up heating (simulation results) at t=0.009
Figure 3.73: δT = 10Celsius heads-up heating (simulation results) at t=0.0185
Figure 3.74: δT = 10Celsius heads-up heating (simulation results) at t=0.037
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3.4 Discussion
Dimensional Analysis
To understand the physical properties that are relevant, a dimensional analysis was
performed. The following parameters are important in describing the physical
properties in this experiment and their physical meanings are summarized in Table
3.2
f (L, g, β, δT, ρ, µ,Cp,U, k) = 0
Relevant physical properties for dimensional analysis:
L : characteristic length (diameter of the eyeball, length of heat source, etc) = [L]
g : gravitational acceleration = [L][T]−2
β :volumetric thermal expansion coefficient = [Θ]−1
δT : temperature difference = [Θ]
ρ : density = [M][L]−3
µ : viscosity = [M][L]−1[T]−1
Cp : specific heat = [L]2[T]−2[Θ]−1
U : velocity = [L][T]−1
k : thermal conductivity = [M][L][T]−3[Θ]−1
M, L,Θ,T : fundamental dimensions, [M] for mass, [L] for length, [T] for time, [Θ]
for temperature
There are nine variables and four fundamental dimensions. According to the Buck-
ingham’s Pi Theorem, five dimensionless groups are expected:
They are:
Π1, Peclet number, which is a measure of the relative importance of convection
versus diffusion:
Π1 =
LρCpU
k
= Pe
Π2, thermal expansion with respect to temperature change:
Π2 = δT β
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Π3, Rayleigh number, associated with buoyancy-driven flow and can be regarded as
a measure of the driving forces of natural convection. The magnitude of Rayleigh
number is a good indication as to whether the natural convection boundary layer is
laminar or turbulent:
Ra =
Cpρ2gβδTL3
kµ
= Ra
Π4 Prandtl number, which is a dimensionless quantity that puts the viscosity of a
fluid in correlation with the thermal conductivity. It therefore assesses the relation
between momentum transport and thermal transport capacity of a fluid ((Ganji and
Kachapi, 2015)):
Π4 =
Cpµ
k
= Pr
Π5 The Reynolds number is the ratio of inertial forces to viscous forces, it is usually
used to determine whether a fluid is in laminar or turbulent flow:
Π5 =
ρUL
µ
= Pr
Since Peclet number, Rayleigh number, and Prandtl number are most relevant to a
natural convection problem, the actual values of these number for each of the three
types of liquid at 21 Celsius were calculated and summarized in Table 3.3 below.
Solution Cp(KJ/kg.K) µ(mPas) k(W/m · K) ρ(kg/m3) β(10−4/K)
Water 4.213 1.731 0.5642 999.9 2.07
Glycerol/Water
Mixture (1:5) 3.826 3.282 0.4985 1051.5 3.18
Glycerol/Water
Mixture (2:5) 3.610 4.647 0.4665 1077.9 3.91
Table 3.2: Corresponding physical property values for each solution
The Peclet number serves as the Reynolds number counterpart for thermal energy
transfer. It represents the ratio of the convection and diffusion fluxes in a flow. In
our study, the Peclet number is on the scale of 102, which indicates that convection
plays a stronger role compared to diffusion in the heat/fluid transport phenomena.
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Solution Pe Pr Ra
Water 168 7.74 6,344
Glycerol/Water Mixture (1:5) 181 13.48 4,316
Glycerol/Water Mixture (2:5) 187 21.68 5,616
Table 3.3: Values of dimensionless numbers in each scenario (Note: L = 5 mm
and delta T = 5 for the characteristic length and temperature difference in Rayleigh
number calculation)
It is also worth noting that the Prandtl number that multiplies the Reynolds number
is Peclet number.
The Prandtl number can be derived by introducing the concept of thermal diffusivity
(α), which describes the rate of temperature spread through a material. It measures
the ability of a material to conduct thermal energy relative to its ability to store
thermal energy. Thermal diffusivity is calculated from the thermal conductivity and
the heat thermal capacity as given below:
α =
k
ρCp
where k is thermal conductivity, ρ is material density, andCp is specific heat capacity
of materials. Therefore, using the idea of thermal diffusivity, the expression for
Prandtl number is given below:
Pr =
Cpµ
k
=
ν
α
where ν is kinematic viscosity, which is the ratio of dynamic viscosity to density.
Therefore, Prandtl number measures the significance of diffusion of momentum
relative to that of heat transfer. The larger the Prandtl number, the thicker will be the
momentum boundary layer compared to the thermal boundary layer. In this study,
Prandtl number is in the range of 10-20, indicating the momentum transport plays a
stronger role compared with heat transport.
The magnitude of Rayleigh number is a good indication as to whether the natural
convection boundary layer is laminar or turbulent. For a Rayleigh number in the
range of 103 to 104, the natural convection boundary layer is laminar. Based on
the value of Peclet number and Prandtl number, it is possible to deduce that heat is
primarily transported via flow convection: fluid that is heated up as the heat source
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carries heat and transports the heat with the flow. The flow circulation continuously
brings colder solution to the heat source. Eventually, the entire solution inside the
eye model is heated up, at which point circulation stops
Baroclinic Torque and Flow Circulation
As mentioned in the previous section, flow circulation patterns were observed re-
gardless of heating position or temperature difference. To understand the formation
of the flow circulation, it is useful to refer to the concept of baroclinic torque.
Baroclinic torque is the source of vorticity, which arises from unequal acceleration
as a result of miss-aligned density gradient and pressure gradient, as shown in the
equation for the transport of vorticity:
Dω
Dt
= −ω(∇ · V) + ∇ρ × ∇p
ρ2
+ (ω · ∇)V + ∇
2ω
Re
where term 1 on the right-hand side represents the effects of expansion on the
vorticity field, term 2 is the baroclinic torque, term 3 describes vortex stretching,
and term 4 describes the effects of viscous diffusion on vorticity distribution. For
the flow fields in our study, term 2 is the only reason that vortices are formed. The
baroclinic torque is the largest when the pressure gradient is perpendicular to the
density gradient. The lighter fluid will be accelerated faster than the heavier fluid,
resulting in a shear layer, and thus generating vorticity. In our case, this variation in
fluid density is caused by thermal heating, and vorticity is generated as a result of
density gradient that is unparalleled with pressure gradient.
Insights from Numerical Simulation Results
To better understand flow activity around the heat source, we refer to the numerical
study conducted by (Shu and Pop, 1997) Their numerical solution investigates the
natural convection from inclined wall plumes that arise from a line thermal source
imbedded at the leading edge of an adiabatic plate with arbitrary tilt angle between
0 and pi/2, and embedded in a fluid-saturated porous medium. The physical model
is demonstrated in Figure 3.75 below.
In our experimental setup, the contact area between the heat source and the eye
model is very small. As we are mostly interested in understanding the fluid motion
around the heat source, the physical model can thus be transformed into the study of
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Figure 3.75: Physical model setup and coordinate system in (Shu and Pop, 1997)
natural convection from inclined wall plumes that arise from a line thermal source
imbedded at the leading edge of a short adiabatic plate (5 mm) with a title angle of
0. This transformation is demonstrated in Figure 3.76 below.
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Figure 3.76: Transformation of the physical model in our study
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The governing equations for this problem are set up as follows:
∂u
∂x
+
∂v
∂y
= 0
∂u
∂x
=
gKβ
ν
(∂T
∂y
cosφ − ∂T
∂x
sinφ)
u
∂T
∂x
+ v
∂T
∂y
= α
∂2T
∂y2
where α is the effective thermal diffusivity of the porous medium, K is permeability
of the porous medium, T is temperature, u,v are velocity components in the x, y
directions, β is coefficient of thermal expansion, φ is the tilt angle measured from
the vertical, and x,y are coordinates along and normal to the plate.
In fluid mechanics, permeability measures the ability of a porous material to allow
fluids to pass through it. Since the only fluid medium in our study is either pure
water or uniform water/glycerol mixture, it is thus assumed a 100% permeability.
Figure 3.77 below shows one of the numerical simulation results: velocity profile
for Ra = 103. The Rayleigh number here is defined as
Ra =
gKβδT x
αν
For a 100% permeability in our case,Ra is then modified to
Ra =
gβδT x3
αν
where x is the effective contact length of the heating piece (x 5 mm). According
to Table 3.3, for δT = 5 Celsius, Rayleigh numbers are 4 ×103 for glycerol/water
(1:5) mixture, and 5 ×103 for glycerol/water (2:5) mixture. Both are on the order of
magnitude of 103. It is seen from Figure 3.77 that if y (perpendicular to adiabatic
plate) is fixed, then u velocity increases as it moves further in the longitudinal
direction. For a fixed x (longitudinal along the adiabatic plate), u velocity drops
as it moves further away into the fluid along the perpendicular direction. This is
consistent with our observations from pathline visualizations.
As mentioned earlier, the contact length between heat source and the eye model
was approximately 5 mm, and thus the characteristic fluid volume near the heat
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Figure 3.77: Representative velocity profiles for Ra = 103
source was determined to be 53mm3. Within this volume, a quick calculation of u
velocity can be performed based on information given in Figure 3.77. For example,
in glycerol/water (1:5) mixture, α = 0.12mm2/s. For y = 1 mm and x = 5 mm, and
φ = 0:
u
α/x = 50
u = 50 × 0.12/5mm/s = 1.2mm/s
This is approximately on the same order of magnitude compared with the actual
maximum velocity reading from our PIV analysis (Table 3.4).
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Heating Method Maximum Velocity (mm/s)
δT = 5-degree center heating 0.2 mm/s
δT = 10-degree center heating 0.4mm/s
δT = 10-degree lower heating 0.4 mm/s
δT = 10-degree upper heating 0.1 mm/s
Table 3.4: Maximum Velocity Reading Near the Wall from PIV Analysis
Summary
In this chapter, facilitating drug mixing in the eye using thermal-driven method
was explored experimentally and the result was successful. For a person sitting in
the upright position, applying a heat source (at least 5 Celsius greater than the eye
temperature) to the lower position of his/her eye can active a strong fluid mixing in
the entire vitreous chamber. Moreover, this method requires the minimal amount of
efforts from patients.
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C h a p t e r 4
CONCLUSION AND FUTURE WORKS
In this study, we explored two methods for inducing drug mixing into the eye after
an intravitreal injection:
1) Motion-driven method: introducing lateral movements to the eye;
2) Thermal-driven: applying heat source to the eye at various heating positions.
The thermal-driven method appears to be more effective in agitating fluid mixings in
the eye. It is also more flexible in dealing with the density variance among different
individuals as well as age groups. In addition, it also provides an alternative to
having a cooling pad in place of a heat source. The idea is the same although
direction of fluid circulation will be the opposite in the case of using a cooling pad.
Of course, whether the thermal-driven method is safe to be included into future
clinical protocols will need more safety investigations. Ultimately, the conclusion
we obtained is very insightful in inspiring us to think about possible minimally
invasive ways to increase intravitreal injection efficacy.
Apart from intravitreal injections, the study outcome can also be useful for applica-
tions in other eye treatment methods, especially for drug-releasing ocular implants.
Since the majority of these ocular implants are designed to provide a sustained
release of medication for a long period which ranges from months to years, a well-
established fluid mixing profile in the eye can certainly help in making sure that
the small amounts of drugs being released can effectively reach the target issue and
eventually achieve an optimal treatment efficacy.
Looking forward, performing the same experiments using animal eyes will certainly
help in understanding the safety features. Based on the observations of important
flow parameters from this study, developing numerical simulations to model the
thermal-driven mixing profile can also be helpful for obtaining explicit understand-
ing of the governing parameters that affect the flow mixing profile. An eye mask
with precision heating ability can also be manufactured and tested to be included as
part of the intravitreal injection protocol. Ultimately, we are hoping that the study
outcome can inspire researchers and ophthalmologists to pay more attention to the
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importance of convective flow in the eye as well as its great potentials in promoting
drug mixing in the eye for improved patient care.
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